LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy23/01/2026
JRL Faces £80m Loss Due To Facades ArmBy News Team21/10/2024 JRL Group’s financial performance has taken a significant hit, with the company posting over £80 million in losses over two years. The main cause of this…
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy23/01/2026